Stokes Frank sold $742K of CSTL

Stokes Frank (Chief Financial Officer) sold 24,908 shares of CASTLE BIOSCIENCES INC (CSTL) at $29.77 ($0.74M total) on 2026-08-14.

Original reporting
SEC EDGAR · Stokes Frank
Published Aug 18, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CSTL
Neutral
medium confidence
Mentioned
$CSTL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by the CFO, including share count, price, and post-transaction holdings.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no new business or financial performance information.

03

What to watch

No 10b5-1 plan is cited, but the filing lacks context on taxes, diversification needs, or pre-existing compensation schedules.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-18, discloses sale executed 2026-08-14.

Background

The article is an SEC Form 4 insider transaction disclosure for CASTLE BIOSCIENCES (CSTL).

Company-level read

Ticker impact

$CSTLNeutralMedium confidence
Context

SEC Form 4 shows CFO Stokes Frank sold 24,908 shares of CSTL for about $741.5K at $29.77 on 2026-08-14.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to near-term sentiment.

Evidence & confidence

The filing is a primary disclosure of an insider transaction, but the article provides no accompanying earnings, guidance, or operational change.

Market effects

Minimal, as this is a single-company insider sale with no sector-wide regulatory or operational signal.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management and does not necessarily reflect negative views on CASTLE BIOSCIENCES fundamentals.

Key entities

  • CASTLE BIOSCIENCES INC

    Company whose insider transaction is disclosed via SEC Form 4.

  • Stokes Frank

    Chief Financial Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CSTLMed

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

Castle Biosciences presented data on DecisionDx-Melanoma at SDPA and Dermato-Onco2026, showing the test can identify higher-risk patients with thin melanomas and provide individualized five-year recurrence-risk estimates. The studies suggest the test refines risk assessment beyond AJCC staging, aiding personalized care. According to the company, the test has been ordered over 260,000 times and is supported by extensive research.

$CSTLMed

Castle Bio (CSTL) Q3 2026 Earnings Call Transcript

Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.

$CSTLHigh

Castle Biosciences Reports Third Quarter 2026 Results

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Third Quarter 2026 Results Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 m

$CSTLHighAI 8/10

Castle Biosciences Reports Third Quarter 2026 Results

Castle Biosciences reported Q3 2026 revenue of $102.9M, up 24% YoY. TissueCypher test volume rose 47% YoY. The company raised full-year 2026 revenue guidance to $385-395M. Q3 net loss was $4.1M, with Adjusted EBITDA of $12.7M. The company presented new data on its DecisionDx-Melanoma test at EADV Congress 2026.

$CSTLMed

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Castle Biosciences presented data at EADV 2026 showing DecisionDx-Melanoma's ability to predict low SLN positivity and high recurrence risk in melanoma patients. The study involved 2,799 patients across 29 U.S. centers, with low-risk patients avoiding SLNB showing 99.6% five-year RFS. The test also stratified recurrence risk in early-stage, transected melanomas, supporting tailored surveillance. Castle Biosciences is a Nasdaq-listed company (CSTL).